Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
about
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelNonmyeloablative allogeneic hematopoietic cell transplantationAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Radioimmunotherapy of human tumoursAllogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantationOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technologyConditioning regimens for hematopoietic cell transplantation: one size does not fit allRadiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maPretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid MalignanciesAnti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftmentThe myth of the second remission of acute leukemia in the adult.Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.Immunotherapy for pediatric leukemia.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemiaWhat is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Optimising the conditioning regimen for acute myeloid leukaemia.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.How to manage high-risk acute myeloid leukemia.Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.Radioimmunotherapy for hematopoietic cell transplantation.Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation.Antibody therapy for acute myeloid leukaemia.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Should persons with acute myeloid leukemia have a transplant in first remission?Reduced-intensity conditioned allogeneic SCT in adults with AML.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Immunotherapy in acute myeloid leukemia.Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
P2860
Q24629826-1A825484-385A-402B-8014-4935E344D59BQ26748780-BDFE0C89-0258-4AB5-8841-61D23C5D9F1EQ27851694-21E93A5D-55FF-4CB8-8664-1ACB91C7D231Q28088825-C8983A20-3CE6-41E2-8599-4ACD32709F41Q30399209-2ED73D46-9E05-4F43-92D4-9DF230C85628Q33398529-2302B096-49FF-46B1-9DF6-87C52958BD12Q33771667-16144AD6-A309-45EA-9B6F-3DAEB701EE19Q33889089-117667C9-EE82-47C2-B627-06100EB93E21Q33917170-3366760B-EA44-48E9-9C09-8540AA8F026BQ34022682-EDF72CEB-08B0-49B3-A0AF-0D1A717C1E1AQ34284225-B98DD129-F23F-4726-AF6A-8CCB2C211132Q35115650-A358B9F5-B1F3-4F48-8CA4-A618F76DBAC3Q35605318-191C156E-1615-49C1-9015-5E65A908919FQ36036263-5D389882-EFD7-4DFA-BF86-B5EB2F5D7341Q36339459-4697D1AD-F794-47C5-83C5-7FE6268E2857Q36474066-5D28483D-1646-4C3B-8097-F2C0D7CBEEE4Q36488985-158D7468-CA97-4AB7-9CA5-47F8C0686640Q36619678-758C1DF7-423A-4F71-8341-445F90280AB8Q36814661-F026D098-5F78-44EE-B963-65D1C5E145C1Q36905562-F0BAD4C7-D651-4DDC-BEAB-615726548AA9Q36968163-EAD06882-497D-4245-9F53-4F721E5729AAQ37000485-92F72632-17DF-439C-A949-6B32B4EDCD78Q37140477-E0B9D572-BC5B-416C-942B-BDAD1DDEF080Q37337422-63A631B6-9756-4A53-9384-A805031F0F59Q37419348-9EB9EFBB-5019-4E64-8993-FB291412C30CQ37644054-D1552CEE-E992-4694-B008-BA04F83A9C18Q37718826-148B38C8-C02D-4A85-8E55-87390AECED32Q37831107-C0BFF3B3-1522-4B7C-B781-4A01B1D0A1FAQ37942816-425E88B8-53EE-465A-928A-501B2AEBDD88Q37960820-40EF8B6A-EB19-4DCE-A270-4B4AC4DAE8E9Q38095962-C9E4D5A9-7B4D-4CBD-AA5E-E5C2071E2E32Q38096058-2638349B-E11B-4EE5-BF6D-6B4606BB4084Q38105635-CA125DD0-6C93-4005-9B1D-97C7A66FEA41Q38169814-CEE11D09-40D2-407A-A5F6-663B21F1FB6AQ38202155-C59A0C1E-31A7-4F31-8E7A-30469AF5D182Q38204207-82F8A9AB-5673-4DDD-B193-5C5632C8F2A5Q38366632-DF930239-B8FC-4B7E-9036-410347D12724Q38488058-6CB6D25D-D097-4B9C-B0B8-09F87136DB12Q38533606-6318F0D4-FD5B-4E12-A527-0499096BA006Q38901125-4857E148-2006-4D92-B092-D1E4697C820B
P2860
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@ast
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@en
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@nl
type
label
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@ast
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@en
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@nl
prefLabel
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@ast
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@en
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@nl
P2093
P2860
P50
P921
P1433
P1476
Allogeneic hematopoietic cell ...... risk myelodysplastic syndrome.
@en
P2093
Dana C Matthews
Darrell R Fisher
John M Pagel
Joseph Rajendran
Paul J Martin
Theodore A Gooley
Wendy A Wilson
P2860
P304
P356
10.1182/BLOOD-2009-03-213298
P407
P50
P577
2009-09-28T00:00:00Z